Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Inhibikase Therapeutics, Inc. (IKT) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Inhibikase Therapeutics, Inc. (IKT), most recent 12 months reported: net loss $60.64M, free cash flow -$42.61M. Latest balance sheet on file: liquid cash $159.02M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): ESTRELLA IMMUNOPHARMA, INC. · EXOZYMES INC. · GREEN PLANET BIOENGINEERING CO., LTD. · GREENLAND MINES LTD · IMMUNOVANT, INC. · IN8BIO, INC. · MiNK Therapeutics, Inc. · INTENSITY THERAPEUTICS, INC.

Stock screener

Watchlist